Eylea HD is a higher dose, longer-acting formulation of Eylea that has been approved to treat Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Eylea is approved to treat these conditions in addition to Macular Edema Following Retinal Vein Occlusion (RVO) and Retinopathy of Prematurity (ROP).

Both are eye injections, but after an initial dosing period, Eylea HD does not have to be given as often as Eylea. Eylea HD is usually administered once every 8 to 12 weeks for DR or 8 to 16 weeks for wAMD and DME. Eylea is usually administered every 4 weeks, which may be extended to once every 8 weeks (2 months), depending on the condition.

Eylea was first approved on November 18, 2011, and Eylea HD was first approved on August 18, 2023.

Both Eylea and Eylea HD are made by Regeneron and there are no differences in their warnings, side effects, interactions, storage, and the way they work.